Today's Date: April 17, 2021
Global COVID-19 Vaccine Inequalities Are Scandalous, Says AHF   •   Biden administration forces taxpayers to fund the trafficking of aborted baby body parts, says Family Research Council   •   New Invention Stops Costly Snags with Face Mask Strings   •     STI Awareness Month: Rachel Zar, Relationship and Sex Therapist on Staying Safe Between the Sheets   •   Make Reading Part of Your Mother's Day Celebration   •   Boutique Air Announces New Las Vegas-Merced Route   •   Wildflower Strengthens Commitment to Black Maternal Health with New Tools, Resources for Black Mothers   •   CUPE Lays Out Priorities for Budget 2021   •   One Voice Children's Choir Uses Their Voices to Raise Awareness of Their Nonprofit with "Little Voice"   •   Labcorp to Webcast Its Annual Meeting of Shareholders   •   Reynolds Consumer Products Inc. to Report First Quarter 2021 Financial Results on May 5, 2021   •   Wrangler® Unveils Global Sustainability Platform: WeCare Wrangler™   •   Half of Kids with Inflammatory Syndrome After COVID-19 Have Neurologic Symptoms   •   Health Foundation of South Florida, Miami-Dade and Broward counties partner to launch locally produced, multi-media COVID vaccin   •   USA Fashion to Manufacture a Collection of Solid Basic Apparel as a Core Offering of its USA Fashion Women’s Clothing Bran   •   Franklin Covey Co. Named to 2021 Training Industry Top 20 Training Companies List For 10th Time For Best-in-Class Leadership Sol   •   /C O R R E C T I O N -- SWAIA/Santa Fe Indian Market/   •   Citizens for a Pro-Business Delaware Joins Pastor Hackett's Protest for Diversity on Chancery Court   •   Cymbiotika Launches Mother’s Day Bundle   •   Government of Canada COVID-19 Update for Indigenous Peoples and communities
Bookmark and Share

The Alzheimer's Drug Discovery Foundation Appoints Karen Harris, Chief Financial Officer, and Dr. Mark Forman, Senior Director o

The Alzheimer's Drug Discovery Foundation Appoints Karen Harris, Chief Financial Officer, and Dr. Mark Forman, Senior Director of Drug Development

Strategic hires strengthen leadership team and position ADDF to expand its notable role in Alzheimer's drug development

PR Newswire

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF), a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announced today a significant expansion of its leadership team with the hiring of Karen Bettauer Harris as chief financial officer and Dr. Mark S. Forman as senior director of drug development.

The two newly created positions reflect the ADDF's growth as it advances its mission to conquer Alzheimer's disease. Harris will report to Mark Roithmayr, chief executive officer of the ADDF, and Dr. Forman will report to Dr. Howard Fillit, founding executive director and chief science officer of the ADDF.

"Today, we support a diverse, robust portfolio of over 40 drug trials spanning all phases of clinical development. Alzheimer's research is progressing at the fastest pace ever and these new hires will help the ADDF evaluate, engage and invest in even more cutting-edge research to help find meaningful treatments and cures," said Dr. Fillit. 

Dr. Forman Brings Unique Background in Biopharmaceutical Industry and Academia

A neuropathologist and neuroscientist, Dr. Mark S. Forman has a track record of leadership in both the biopharmaceutical industry and academia. Dr. Forman will provide scientific leadership and strategic direction, overseeing the ADDF's core drug development portfolio, which currently supports over 40 active preclinical and clinical research programs at leading medical institutions and biotech companies. He will also work with the Chief Science Officer to provide strategic direction and facilitate the formation of interdisciplinary drug development teams.

Dr. Forman joins the ADDF from Acadia Pharmaceuticals, where he served as Vice President and Head of Translational Medicine, contributing to the development of a treatment for hallucinations and delusions associated with dementia-related psychosis. He also spent 12 years at Merck as Executive Director and Neuroscience Lead in Translational Medicine, responsible for their neuroscience portfolio in early clinical development, including the development of more than 20 novel therapeutics.

Before his time in the biopharmaceutical industry, Dr. Forman was an Assistant Professor of Pathology at the University of Pennsylvania, where his research focused on the pathogenesis of neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia (FTD). His work has earned him several awards, including the 2012 PhRMA Research and Hope Award. He received his medical degree from Duke University School of Medicine and doctorate in immunology from Rockefeller University.

Harris Adds Finance and Investment Expertise

A senior finance executive, Karen Bettauer Harris brings extensive nonprofit and investment banking experience to her role as Chief Financial Officer. She will lead the ADDF's financial administration and policy, budgeting, and business planning, working closely with the Board, Treasurers and the Finance and Audit Committee. She comes to the ADDF from East Harlem Tutorial Program, where she oversaw all areas of finance, audit financial planning, and reporting. During her tenure at Merrill Lynch, she primarily focused on biotech industries and the healthcare sector. Harris received her MBA in Finance from Stanford Graduate School of Business and a BA in Economics from Columbia University.

"We are thrilled to welcome Karen and Mark to the ADDF," said Roithmayr. "The creation of these new roles signals the great successes the ADDF has achieved as a result of our research investments in recent years. With the ADDF's venture philanthropy model, when drugs we have supported move into the next exciting phase of development, we get a return on our investment which we then re-invest in research to boost the next great idea. Their expertise will be a huge asset as we continue to see our investments pay off and move closer to a cure."

About the Alzheimer's Drug Discovery Foundation (ADDF)

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $168 million to fund over 650 Alzheimer's drug discovery and biomarker programs and clinical trials in 19 countries. To learn more, please visit:

Cision View original content to download multimedia:

SOURCE Alzheimer's Drug Discovery Foundation

Back to top
| Back to home page

White House Live Stream
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News